Clôture précédente | 101,40 |
Ouverture | 100,20 |
Offre | S.O. x S.O. |
Vente | S.O. x S.O. |
Var. jour | 100,20 - 101,60 |
Sur 52 semaines | 95,40 - 110,00 |
Volume | |
Volume moyen | 0 |
Cap. boursière | 260,608B |
Bêta (mensuel sur 5 ans) | S.O. |
Rapport P/E (sur 12 mois) | 21,04 |
BPA (sur 12 mois) | S.O. |
Date de bénéfices | 25 avr. 2024 |
Dividende et rendement à terme | S.O. (S.O.) |
Date ex-dividende | S.O. |
Objectif sur 1 an | S.O. |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant